Vetmedin 1.25 mg Chewable Tablets for Dogs

The veterinary medicinal product has not been tested in cases of asymptomatic DCM
in Dobermans with atrial fibrillation or sustained ventricular tachycardia.
The veterinary medicinal product has not been tested in cases of asymptomatic
myxomatous mitral valve disease in dogs with significant supraventricular and/or
ventricular tachyarrhythmia.

Special precautions for safe use in the target species:
The blood glucose should be tested regularly during treatment in dogs with existing
diabetes mellitus.
For use in the preclinical stage of dilated cardiomyopathy (asymptomatic with an
increase in left ventricular end-systolic and end-diastolic diameter), a diagnosis
should be made by means of a comprehensive cardiac examination (incl.
echocardiographic examination and possibly Holter monitoring).
For use in the preclinical stage of myxomatous mitral valve disease (stage B2,
according to ACVIM consensus: asymptomatic with mitral murmur ≥3/6
cardiomegaly due to myxomatous mitral valve disease), a diagnosis should be made
by means of a comprehensive physical and cardiac examination which should
include echocardiography or radiography where appropriate.
Monitoring of cardiac function and morphology is recommended in animals treated
with pimobendan.
The chewable tablets are flavoured. In order to avoid any accidental ingestion, store
tablets out of reach of the animals.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Wash hands after use.
AN: 01122/2025Page 3 of 7
Advice to doctors: accidental ingestion, especially by a child, may lead to the
occurrence of tachycardia, orthostatic hypotension, flushing of the face and
headaches.
Close bottle tightly with cap directly after removal of the required number of tablets.
Special precautions for the protection of the environment:
Not applicable.